Pathogenesis and management of type 2 neurofibromatosis

Bibliography

• Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010;152A(2):327-32
   PubMed Web of Science ®Google Scholar
• Evans DG, Ramsden RT, Shenton A, et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 2007;44(7):424-8
   PubMedGoogle Scholar
• Baser ME, Friedman JM, Wallace AJ, et al. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 2002;59(11):1759-65
   PubMed Web of Science ®Google Scholar
• Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet 2009;373(9679):1974-86
   PubMed Web of Science ®Google Scholar
• Evans DG, Trueman L, Wallace A, et al. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 1998;35(6):450-5
   PubMedGoogle Scholar
• Mérel P, Hoang-Xuan K, Sanson M, et al. Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer 1995;12(2):117-27
   PubMedGoogle Scholar
• Parry DM, MacCollin MM, Kaiser-Kupfer MI, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996;59(3):529-39
   PubMedGoogle Scholar
• Baser ME, Kuramoto L, Joe H, et al. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. Am J Hum Genet 2004;75(2):231-9
   PubMedGoogle Scholar
• Selvanathan SK, Shenton A, Ferner R, et al. Further genotype–phenotype correlations in neurofibromatosis 2. Clin Genet 2010;77(2):163-70
   PubMed Web of Science ®Google Scholar
• Baser ME, Kuramoto L, Woods R, et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet 2005;42(7):540-6
   PubMedGoogle Scholar
• Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 1999;81(6):496-9
   PubMedGoogle Scholar
• Choi JW, Lee JY, Phi JH, et al. Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2. J Neurosurg Pediatr 2014;13(6):650-7
   PubMedGoogle Scholar
• Nunes F, MacCollin M. Neurofibromatosis 2 in the pediatric population. J Child Neurol 2003;18(10):718-24
   PubMedGoogle Scholar
• Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84(304):603-18
   PubMedGoogle Scholar
• Kluwe L, Mautner V, Heinrich B, et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003;40(2):109-14
   PubMed Web of Science ®Google Scholar
• Feucht M, Kluwe L, Mautner VF, Richard G. Correlation of nonsense and frameshift mutations with severity of retinal abnormalities in neurofibromatosis 2. Arch Ophthalmol 2008;126(10):1376-80
   PubMedGoogle Scholar
• Mohyuddin A, Neary WJ, Wallace A, et al. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet 2002;39(5):315-22
   PubMed Web of Science ®Google Scholar
• Aghi M, Kluwe L, Webster MT, et al. Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype. J Neurosurg 2006;104(2):201-7
   PubMedGoogle Scholar
• Zirn B, Arning L, Bartels I, et al. Ring chromosome 22 and neurofibromatosis type II: proof of two-hit model for the loss of the NF2 gene in the development of meningioma. Clin Genet 2012;81(1):82-7
   PubMedGoogle Scholar
• Dumanski JP, Carlbom E, Collins VP, Nordenskjöld M. Deletion mapping of a locus on human chromosome 22 involved in the oncogenesis of meningioma. Proc Natl Acad Sci U S A 1987;84(24):9275-9
   PubMedGoogle Scholar
• Seizinger BR, Rouleau G, Ozelius LJ, et al. Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis. Science 1987;236(4799):317-19
   PubMed Web of Science ®Google Scholar
• Hanemann CO, Diebold R, Kaufmann D. Role of NF2 haploinsufficiency in NF2-associated polyneuropathy. Brain Pathol 2007;17(4):371-6
   PubMedGoogle Scholar
• Stemmer-Rachamimov AO, Gonzalez-Agosti C, Xu L, et al. Expression of NF2-encoded merlin and related ERM family proteins in the human central nervous system. J Neuropathol Exp Neurol 1997;56(6):735-42
   PubMedGoogle Scholar
• Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72(5):791-800
   PubMed Web of Science ®Google Scholar
• Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363(6429):515-21
   PubMed Web of Science ®Google Scholar
• Sher I, Hanemann CO, Karplus PA, Bretscher A. The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state. Dev Cell 2012;22(4):703-5
   PubMedGoogle Scholar
• Qi Q, Liu X, Brat DJ, Ye K. Merlin sumoylation is required for its tumor suppressor activity. Oncogene 2014;33(41):4893-903
   PubMedGoogle Scholar
• Gladden AB, Hebert AM, Schneeberger EE, McClatchey AI. The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex. Dev Cell 2010;19(5):727-39
   PubMedGoogle Scholar
• Gonzalez-Agosti C, Xu L, Pinney D, et al. The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene 1996;13(6):1239-47
   PubMedGoogle Scholar
• Murthy A, Gonzalez-Agosti C, Cordero E, et al. NHE-RF, a regulatory cofactor for Na(+)-H+ exchange, is a common interactor for merlin and ERM (MERM) proteins. J Biol Chem 1998;273(3):1273-6
   PubMedGoogle Scholar
• Morrison H, Sherman LS, Legg J, et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001;15(8):968-80
   PubMed Web of Science ®Google Scholar
• Yi C, Troutman S, Fera D, et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin’s regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 2011;19(4):527-40
   PubMed Web of Science ®Google Scholar
• Zhang N, Bai H, David KK, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010;19(1):27-38
   PubMed Web of Science ®Google Scholar
• Hamaratoglu F, Willecke M, Kango-Singh M, et al. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2006;8(1):27-36
   PubMed Web of Science ®Google Scholar
• Lallemand D, Manent J, Couvelard A, et al. Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas. Oncogene 2009;28(6):854-65
   PubMedGoogle Scholar
• Kaempchen K, Mielke K, Utermark T, et al. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet 2003;12(11):1211-21
   PubMedGoogle Scholar
• Kissil JL, Wilker EW, Johnson KC, et al. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 2003;12(4):841-9
   PubMedGoogle Scholar
• Rong R, Tang X, Gutmann DH, Ye K. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc Natl Acad Sci U S A 2004;101(52):18200-5
   PubMedGoogle Scholar
• James MF, Han S, Polizzano C, et al. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 2009;29(15):4250-61
   PubMed Web of Science ®Google Scholar
• López-Lago MA, Okada T, Murillo MM, et al. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009;29(15):4235-49
   PubMed Web of Science ®Google Scholar
• Ammoun S, Flaiz C, Ristic N, et al. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res 2008;68(13):5236-45
   PubMed Web of Science ®Google Scholar
• Morrison H, Sperka T, Manent J, et al. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 2007;67(2):520-7
   PubMed Web of Science ®Google Scholar
• Li W, You L, Cooper J, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 2010;140(4):477-90
   PubMed Web of Science ®Google Scholar
• Dirks MS, Butman JA, Kim HJ, et al. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg 2012;117(1):109-17
   PubMedGoogle Scholar
• Slattery WHIII, Fisher LM, Hitselberger W, et al. Hearing preservation surgery for neurofibromatosis Type 2-related vestibular schwannoma in pediatric patients. J Neurosurg 2007;106(4 Suppl):255-0
   PubMedGoogle Scholar
• Peyre M, Stemmer-Rachamimov A, Clermont-Taranchon E, et al. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation. Oncogene 2013;32(36):4264-72
   PubMedGoogle Scholar
• Abaza MM, Makariou E, Armstrong M, Lalwani AK. Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 1996;106(6):694-9
   PubMedGoogle Scholar
• Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38(5):880-5; discussion 885-6
   PubMed Web of Science ®Google Scholar
• Plotkin SR, Merker VL, Muzikansky A, et al. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol 2014;35(1):e50-6
   PubMed Web of Science ®Google Scholar
• Plotkin SR, Stemmer-Rachamimov AO, Barker FGII, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361(4):358-67
   PubMed Web of Science ®Google Scholar
• Kontorinis G, Nichani J, Freeman SR, et al. Progress of hearing loss in neurofibromatosis type 2: implications for future management. Eur Arch Otorhinolaryngol 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Evans DG, Baser ME, O’Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 2005;19(1):5-12
   PubMed Web of Science ®Google Scholar
• Samii M, Matthies C, Tatagiba M. Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2. Neurosurgery 1997;40(4):696-705; discussion 705-6
   PubMed Web of Science ®Google Scholar
• Jääskeläinen J, Paetau A, Pyykkö I, et al. Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases. J Neurosurg 1994;80(3):541-7
   PubMedGoogle Scholar
• Dewan R, Pemov A, Kim HJ, et al. Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neuro Oncol 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Samii M, Gerganov V, Samii A. Microsurgery management of vestibular schwannomas in neurofibromatosis type 2: indications and results. Prog Neurol Surg 2008;21:169-75
   PubMedGoogle Scholar
• MacNally SP, Rutherford SA, King AT, et al. Outcome from surgery for vestibular schwannomas in children. Br J Neurosurg 2009;23(3):226-31
   PubMed Web of Science ®Google Scholar
• Plotkin SR, O’Donnell CC, Curry WT, et al. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. J Neurosurg Spine 2011;14(4):543-7
   PubMedGoogle Scholar
• Rowe JG, Radatz MW, Walton L, et al. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry 2003;74(9):1288-93
   PubMedGoogle Scholar
• Rowe J, Radatz M, Kemeny A. Radiosurgery for type II neurofibromatosis. Prog Neurol Surg 2008;21:176-82
   PubMedGoogle Scholar
• Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 2007;60(3):460-8; discussion 468-70
   PubMedGoogle Scholar
• Phi JH, Kim DG, Chung HT, et al. Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation. Cancer 2009;115(2):390-8
   PubMedGoogle Scholar
• Roche PH, Robitail S, Thomassin JM, et al. [Surgical management of vestibular schwannomas secondary to type 2 neurofibromatosis]. Neurochirurgie 2004;50(2-3 Pt 2):367-76
   PubMedGoogle Scholar
• Sharma MS, Singh R, Kale SS, et al. Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2. J Neurooncol 2010;98(2):265-70
   PubMedGoogle Scholar
• Chan AW, Black P, Ojemann RG, et al. Stereotactic radiotherapy for vestibular schwannomas: favorable outcome with minimal toxicity. Neurosurgery 2005;57(1):60-70; discussion 60-70
   PubMed Web of Science ®Google Scholar
• Combs SE, Volk S, Schulz-Ertner D, et al. Management of acoustic neuromas with fractionated stereotactic radiotherapy (FSRT): long-term results in 106 patients treated in a single institution. Int J Radiat Oncol Biol Phys 2005;63(1):75-81
   PubMedGoogle Scholar
• Fuss M, Debus J, Lohr F, et al. Conventionally fractionated stereotactic radiotherapy (FSRT) for acoustic neuromas. Int J Radiat Oncol Biol Phys 2000;48(5):1381-7
   PubMed Web of Science ®Google Scholar
• Meijer OW, Vandertop WP, Lagerwaard FJ, et al. Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2. Neurosurgery 2008;62(5 Suppl):A37-42; discussion A42-3
   Google Scholar
• Vachhani JA, Friedman WA. Radiosurgery in patients with bilateral vestibular schwannomas. Stereotact Funct Neurosurg 2007;85(6):273-8
   PubMedGoogle Scholar
• Thomsen J, Mirz F, Wetke R, et al. Intracranial sarcoma in a patient with neurofibromatosis type 2 treated with gamma knife radiosurgery for vestibular schwannoma. Am J Otol 2000;21(3):364-70
   PubMedGoogle Scholar
• Rowe J, Grainger A, Walton L, et al. Safety of radiosurgery applied to conditions with abnormal tumor suppressor genes. Neurosurgery 2007;60(5):860-4; discussion 860-4
   PubMedGoogle Scholar
• Baser ME, Evans DG, Jackler RK, et al. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer 2000;82(4):998
   PubMedGoogle Scholar
• Zhang M, Chang SD. Outcomes following malignant degeneration of benign vestibular schwannomas after stereotactic radiosurgery. World Neurosurg 2014;82(3-4):346-9
   PubMedGoogle Scholar
• Moffat DA, Lloyd SK, Macfarlane R, et al. Outcome of translabyrinthine surgery for vestibular schwannoma in neurofibromatosis type 2. Br J Neurosurg 2013;27(4):446-53
   PubMed Web of Science ®Google Scholar
• Shuto T, Inomori S, Matsunaga S, Fujino H. Microsurgery for vestibular schwannoma after gamma knife radiosurgery. Acta Neurochir (Wien) 2008;150(3):229-34; discussion 234
   PubMedGoogle Scholar
• Ammoun S, Cunliffe CH, Allen JC, et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol 2010;12(8):834-43
   PubMedGoogle Scholar
• Blair KJ, Kiang A, Wang-Rodriguez J, et al. EGF and bFGF promote invasion that is modulated by PI3/Akt kinase and Erk in vestibular schwannoma. Otol Neurotol 2011;32(2):308-14
   PubMedGoogle Scholar
• Plotkin SR, Halpin C, McKenna MJ, et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 2010;31(7):1135-43
   PubMed Web of Science ®Google Scholar
• Karajannis MA, Legault G, Hagiwara M, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 2012;14(9):1163-70
   PubMedGoogle Scholar
• Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 2013;81(21 Suppl 1):S33-40
   PubMed Web of Science ®Google Scholar
• Karajannis MA, Legault G, Hagiwara M, et al. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 2014;16(2):292-7
   PubMedGoogle Scholar
• Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 2012;33(6):1046-52
   PubMed Web of Science ®Google Scholar
• Thornton AR, Raffin MJ. Speech-discrimination scores modeled as a binomial variable. J Speech Hear Res 1978;21(3):507-18
   PubMedGoogle Scholar
• Alanin MC, Klausen C, Caye-Thomasen P, et al. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Mautner VF, Nguyen R, Knecht R, Bokemeyer C. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 2010;21(11):2294-5
   PubMedGoogle Scholar
• Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 2010;12(1):14-18
   PubMedGoogle Scholar
• Eminowicz GK, Raman R, Conibear J, Plowman PN. Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy. J Laryngol Otol 2012;126(1):79-82
   PubMedGoogle Scholar
• Subbiah V, Slopis J, Hong DS, et al. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol 2012;30(5):e64-8
   Google Scholar
• Hawasli AH, Rubin JB, Tran DD, et al. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base 2013;74(3):136-41
   PubMedGoogle Scholar
• Slusarz KM, Merker VL, Muzikansky A, et al. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 2014;73(6):1197-204
   PubMed Web of Science ®Google Scholar
• Goutagny S, Raymond E, Sterkers O, et al. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 2011;22(4):990-1
   PubMed Web of Science ®Google Scholar
• Nunes FP, Merker VL, Jennings D, et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One 2013;8(3):e59941
   PubMed Web of Science ®Google Scholar
• Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 2012;109(1):63-70
   PubMed Web of Science ®Google Scholar
• Green RM, Cloughesy TF, Stupp R, et al. Bevacizumab for recurrent ependymoma. Neurology 2009;73(20):1677-80
   PubMedGoogle Scholar
• Gururangan S, Fangusaro J, Young Poussaint T, et al. Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma–a Pediatric Brain Tumor Consortium study. Neuro Oncol 2012;14(11):1404-12
   PubMedGoogle Scholar
• Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 2015;17(1):116-21
   PubMed Web of Science ®Google Scholar